Breakthrough: New European Guidelines Suggest Better Management of Fistulas for Patients with Hidradenitis Suppurativa
The new European guidelines for treating hidradenitis suppurativa (HS) were presented at EADV 2024. The guidelines highlight the effectiveness of two new agents, bimekizumab and secukinumab, in treating moderate to severe HS, particularly in addressing draining fistulas. Dr Thrasyvoulos Tzellos explains the guidelines in this MEDtalk.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in